Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection

Launched by FUDAN UNIVERSITY · Dec 15, 2015

Keywords

ClinConnect Summary

This clinical trial is looking at how effective adjuvant radiotherapy (a type of treatment using high-energy rays) is for patients with stage II or III thymoma after their tumors have been completely removed through surgery. The goal is to see if adding this treatment can help patients live longer and improve their overall health after surgery.

To be eligible for this trial, participants should be between 18 and 75 years old and have a specific type of thymoma that has been confirmed by a doctor. They should also be in reasonably good health and have had their tumor completely removed within the last three months. However, individuals with certain conditions, such as distant spread of cancer or those who have recently received other cancer treatments, cannot participate. If you join the study, you will receive close monitoring and support from the medical team throughout the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18\~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed masaoka stage II or III thymoma; Have adequate bone marrow, hepatic, and renal function; Patients receive complete resection within 3 months; Written informed consent.
• Exclusion Criteria:
• • Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.